Highlights

The vaccine will be affordable & accessible
Cervical cancer in India ranks as the second-most frequent cancer among women
Phase three results showed a robust immune response in 100% of the vaccine recipients

Latest news

CWG Table Tennis: Sharath Kamal & Sathiyan Gnanasekharan fall at the final hurdle in Men’s Doubles

CWG India's Day 11 full schedule: IND vs AUS Hockey Gold Badminton Sindhu Lakshya Sen fixture on August 8

Viral video puts SpiceJet in more trouble? Passengers walk on tarmac amid bus delay, DGCA probing: report

Bihar to hire shooters to cull nilgai, wild boar after crop damage complaints by farmers

CWG: World Champion Nikhat Zareen wins 50 kg title at Birmingham 2022

Good news! India to launch cervical cancer vaccine by year-end

Cervical Cancer Vaccine : The Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine by the end of this year.

Updated: Jul 26, 2022 07:43

Editorji News Desk

Cancer Vaccine: After the Drugs Controller General of India's (DCGI) approval, the Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine later this year.

According to SII, the Quadrivalent Human Papillomavirus vaccine (qHPV) to treat cervical cancer in women will be affordable and accessible.

Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age. The vaccine is based on VLP (virus-like particles), similar to the Hepatitis B vaccine and protects by generating antibodies against the HPV virus L1 protein.

The trials for the vaccine started in 2019 and thousands of participants in the age group of 9‐26 years were part of the trials across India. Phase three results showed a robust immune response in 100 per cent of the vaccine recipients with good safety records.

Also watch: Researchers develop a new single-shot vaccine to cure AIDS